India enforced ‘Schedule M’ for drug manufacturers, emphasizing quality, recall systems. Companies must comply with strict rules on hygiene, audits, and reporting defects to DCGI for improved drug quality and safety measures. For seamless implementation of the new rules, the health ministry has been conducting workshops and giving presentations to pharma companies.
